Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of HM10460A versus pegfilgrastim for chemotherapy-induced neutropenia in breast cancer
2013-003094-10Phase 2Completed
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of esketamine in neutropenia and breast cancer (2 arms), sponsored by Spectrum Pharmaceuticals, Inc. Primary endpoint: Duration of severe neutropenia during Cycle 1. Started Sep 2013; status: completed.
02
Drugs
esketamine
03
Conditions
neutropeniabreast cancer
Beyond the preview
Go deeper on 2013-003094-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003094-10.